Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Siddharth Bhansali

Interventional Cardiology New Orleans, LA Medical Doctor

NPI 1912999046 CMS profile 788186

2633 Napoleon Ave, Suite 500, New Orleans, LA 70115

Open in the dashboard

General payments

$4,922

241 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Siddharth Bhansali of New Orleans, LA is reported in the CMS Open Payments database as having received $4,922 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $962 47
2024 General $1,098 56
2023 General $1,276 60
2022 General $721 40
2021 General $493 23
2020 General $318 12
2019 General $55 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Siddharth Bhansali
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Siddharth Bhansali were reported at $962. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Siddharth Bhansali Interventional Cardiology median Middle half National median
2019 $55 $1,097 $329–$3,048 $163
2020 $318 $473 $161–$1,480 $114
2021 $493 $677 $233–$1,827 $132
2022 $721 $978 $333–$2,724 $149
2023 $1,276 $1,136 $382–$2,986 $160
2024 $1,098 $1,181 $395–$3,326 $164
2025 $962 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $715 45 payments
  2. Janssen Pharmaceuticals, Inc $596 34 payments
  3. Amgen Inc. $562 26 payments
  4. E.R. Squibb & Sons, L.L.C. $398 16 payments
  5. Merck Sharp & Dohme Corporation $370 21 payments
  6. AstraZeneca Pharmaceuticals LP $368 20 payments
  7. Esperion Therapeutics, Inc. $297 16 payments
  8. Sanofi-Aventis U.S. LLC $194 9 payments
  9. Novo Nordisk Inc $170 8 payments
  10. Pfizer Inc. $149 9 payments
  11. Other $1,102 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,887 239 payments
  2. Education $36 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $596 34 payments
  2. Repatha $518 24 payments
  3. VERQUVO $484 28 payments
  4. FARXIGA $368 20 payments
  5. LEQVIO $328 22 payments
  6. NEXLETOL $297 16 payments
  7. ENTRESTO $290 18 payments
  8. CAMZYOS $256 9 payments
  9. FLOWTRIEVER CATHETER, S $202 2 payments
  10. MULTAQ $152 7 payments
  11. Other $1,694 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

8,136

Median for Interventional Cardiology: 2,236

Drug cost

$1,998,419

Median for Interventional Cardiology: $380,412

Branded share of claims

25.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 384 $381,156
Xarelto Rivaroxaban Brand 274 $313,375
Vyndamax Tafamidis Brand 11 $246,892
Entresto Sacubitril/Valsartan Brand 219 $231,252
Jardiance Empagliflozin Brand 185 $189,936
Ozempic Semaglutide Brand 96 $115,395
Mounjaro Tirzepatide Brand 85 $108,994
Repatha Sureclick Evolocumab Brand 67 $68,351
Nexletol Bempedoic Acid Brand 80 $59,356
Farxiga Dapagliflozin Propanediol Brand 62 $42,283

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$116,730

Medicare's payments for the services billed

Medicare patients

547

Average age 75

Services billed

2,139

283 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 36%
Atrial fibrillation 28%
Chronic kidney disease 28%
Diabetes 27%
Heart failure 22%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $187
$187 219 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $161
$161 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $157
$157 274 —
VERQUVO
  • Merck Sharp & Dohme Corporation $114
$114 12 —
Repatha
  • Amgen Inc. $78
$78 67 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record